Kornimate/medical-research-clean huggingface dataset:
laser vaginal treatment for gsm

Conditions: Menopausal Urethral Atrophy; Vulvar Atrophy

Summary: genitourinary syndrome of menopause (gsm) due to low estrogen levels affects about half of post-menopausal women and may have a dramatic impact on women's quality of life. women complain of vaginal dryness, itching, discomfort, malodour, painful intercourse and may have urinary urgency, irritation, bladder/urethral pain and recurring bladder infections. first-line therapies include vaginal moisturizers, lubricants and estrogen (either oral or with vaginal cream/tablets). while these therapies are effective, the ongoing costs and the resistance to the indefinite use of vaginal creams/inserts is a challenge to the continued use of these therapies. recently, an innovative laser therapy has been used to treat women with gsm. a randomized controlled trial (rct) to study how effective the laser is to treat women with gsm is planned.


Eligibility criteria:
inclusion criteria: 1. females aged 45-70 years; 2. 2 or more years since last natural menstrual period, or surgical menopause (bilateral oophorectomy); 3. at least 1 vaginal symptom reported from the following list, experienced for the past 30 days which is moderate or severe at least once a week: dryness \| itching \| irritation \| soreness/pain \| dyspareunia; 4. no concurrent or new planned treatment for gsm during the treatment period and the 3 months following it; 5. vaginal anatomy allows for laser therapy; 6) willing and able to comply with the study protocol. exclusion criteria: 1. patient is pregnant/lactating 2. unexplained abnormal genital bleeding 3. current acute vaginal/ bladder infection 4. antibiotic use the past 30 days; 5. women under age 55 with endometrial ablation/ hysterectomy/ at least one ovary; 6. concurrent use of any other new gsm treatment 7. pelvic surgery \<3 months 8. current treatment for chronic pelvic pain
a study to evaluate onm100, an intraoperative fluor imaging agent for the detection of peri mets

Conditions: Peritoneal Carcinomatosis

Summary: peritoneal carcinomatosis (pc) results from the metastasis of a primary cancer of the peritoneum (e.g., appendiceal, ovarian, uterine, colorectal, and gastric cancers) that then disseminates throughout the abdominal cavity. historically progression to pc was considered terminal and resulted in survival times on the scale of a few months with palliative care being the best option for patients. more recently, cytoreductive surgery (cs) has emerged as a means to prolong and improve patient lives with a median increase in survival of up to \~5 years. it has been reported that for every 10% increase in cytoreduction there is a 5.5% increase in median survival time. in addition to surgical tumor debulking within the peritoneal space, it has also been shown that coupling surgical intervention with hyperthermic intraperitoneal chemotherapy (hipec) can have an even greater impact on patient outcomes. pegsitacianine, a micellar fluorescence agent, exploits the ubiquitous ph differences observed between cancerous and normal tissues. this in turn, provides a highly sensitive and specific fluorescence response after localizing within the tumor microenvironment, thus allowing the detection of primary tumors, their margins, metastatic disease, and tumor-containing lymph nodes.


Eligibility criteria:
inclusion criteria: * imaging and biopsy confirmed metastatic disease of peritoneal origin exclusion criteria: * known hypersensitivity or allergy to any component of pegsitacianine * tumor locations the surgeon deems unfeasible to image intraoperatively * excessive and/or generalized metastatic disease deemed inoperative by the surgeon
study of shr0302 tablets (shr0302) as monotherapy in active rheumatoid arthritis (ra) patients

Conditions: Rheumatoid Arthritis

Summary: to evaluate the safety and efficacy of shr0302 tablets (shr0302) in subjects with moderate to severe active rheumatoid arthritis.


Eligibility criteria:
inclusion criteria: * male or female subjects who are 18 - 70 (inclusive) years of age on the day of signing informed consent * have a diagnosis of ra meeting the 2010 acr/eular criteria of ra and acr functional class i-iii * have ≥6 swollen joints (from a 66-joint count) and ≥8 tender joints (from a 68-joint count) at screening and at baseline, screening serum c-reactive protein (crp)or hscrp \> 1.2 x upper limit of laboratory normal range (uln),or erythrocyte sedimentation rate (esr) \> 28 mm/h * have not used any disease modifying anti-rheumatic drug (dmard) or have an inadequate response to one or more kinds of conditional dmards (methotrexate, leflunomide, chloroquine, hydroxychloroquine, sulfasalazine, minocycline, penicillamine, auranofin or injection gold preparation, and iguratimod) due to lack of efficacy or toxicity, and have agreed to be washed out from these conditional dmards for a period of at least 7 t1/2s prior to randomization, with the exception of antimalarials, which must be at a stable dose for at least 12 weeks prior to randomization * body mass index (bmi = weight/height squared (kg/m2)) within the range of 18 to 35, exclusion criteria: * current or previous ra treatment with a jak inhibitor * current or previous ra treatment with a biologic dmard
diagnosis and management of myofascial pain syndrome in women with mastectomies

Conditions: Breast Cancer; Myofascial Trigger Point

Summary: myofascial pain considerably affects women undergoing treatment for breast cancer, is characterized by the presence of myofascial taut bands and trigger points. this study aims to evaluate the effects of ischemic compression, high-voltage electrical stimulation and rehabilitation of kinesio in women with myofascial pain following treatment of breast cancer. this is a randomized blind controlled study. for this, we invited 60 volunteers undergoing treatment for breast cancer, randomized and allocated into three groups: g1 (cinesioterapia), g2 (ischemic compression cinesioterapia +) and g3 (high voltage electrical stimulation cinesioterapia +). the stance, the plantar pressure distribution and the balance will be assessed by means of photogrammetry and baropodometry respectively. myofascial trigger points will be assessed with the use of infrared thermography, algometry and numerical rating scale of pain (end). moreover, the quality of life of the volunteers will be assessed by the functional assessment of cancer therapy-breast (fact-b +4). the volunteers will undergo 10 sessions of treatment, and reassessed at the end of treatment and after thirty days. normality test is used to verify data distribution and consistent statistical test for proper intra and comparisons between groups, being thus considered two factors in the comparisons, time and group. a significance level of 5% is assumed.


Eligibility criteria:
inclusion criteria: * mastectomy * aged between 35 and 70 years * myofascial trigger point in the upper trapezius muscle exclusion criteria: * metastasis or recurrence of breast cancer * bilateral mastectomy * in physiotherapy treatment * degenerative diseases of the spine * use of muscle relaxants or anti-inflammatory analgesics in the last week * report of fibromyalgia

Keywords: breast neoplasms mastectomy myofascial pain syndromes physical therapy modalities
whey protein and carbohydrates in eras for recovery after thyroidectomy: a cohort study

Conditions: Whey Protein; Thyroid Neoplasms; Neck Dislocation; Enhanced Recovery After Surgery

Summary: exploring the effects of whey protein combined with carbohydrates in an enhanced recovery after surgery (eras) protocol on the postoperative recovery of thyroid cancer patients undergoing lateral neck dissection, aiming to provide more precise research and guidance for the perioperative accelerated recovery plan in such patients. the goal is to accelerate postoperative recovery and reduce postoperative complications for thyroid cancer patients undergoing neck dissection.

perioperative dietary management was differentiated between the two groups: experimental group: 6 hours before surgery, patients orally consumed 250 ml of a full-nutrition liquid (220 ml homogenized diet, 50 g; containing 31.4 g carbohydrates, 8 g protein, and 215 kcal). 2 hours before surgery, patients orally consumed 200 ml of a clear liquid (50 g enzymatically hydrolyzed rice powder + 0.5 g low-sodium salt; containing 47.7 g carbohydrates, 6.5 g whey protein, and 193 kcal). after surgery, once there were no symptoms such as dizziness or vomiting, patients could start consuming clear liquids (containing 47.7 g carbohydrates, 6.5 g protein, and 221 kcal) orally every 30 minutes, 4 times on the day of surgery. starting from the first day after surgery, patients consumed 200 ml of fat-free nutritional liquid (50 g enzymatically hydrolyzed rice powder + 7.5 g isolated whey protein + 0.5 g low-sodium salt; 223 kcal) per serving, 4 to 6 times per day as needed. control group: patients fasted for 12 hours before surgery, and after surgery, intravenous fluids were administered. fat-free diet began after 24 hours post-surgery. discharge criteria: the discharge time was determined by the surgeon based on the patient's postoperative drainage condition and the presence or absence of complications.

Eligibility criteria:
inclusion criteria: * aged 18 years or older; * differentiated thyroid cancer with lateral lymph node dissection; * written informed consent provided by the participant. exclusion criteria: * history of chronic liver or kidney disease, ischemic heart disease, or diabetes; * previous neck surgery or history of iodine-131 radiation; * allergy to soy or whey protein; * intraoperative chylous leak; * other special types of thyroid cancer.
effect of intrathecal vs intraarticular dexmedetomidine on postoperative pain following arthroscopy

Conditions: Postoperative Pain

Summary: comparison between intrathecal dexmedetomidine versus intraarticular dexmedetomidine on postoperative pain after knee arthroscopy.


Eligibility criteria:
inclusion criteria: * adult patients, asa i-ii, undergoing knee arthroscopy under spinal anesthesia. exclusion criteria: * absolute or relative contraindications to spinal anesthesia, allergy to dexmedetomidine or chronic pain treatment.
drug compliance and affecting factors in juvenile idiopathic arthritis

Conditions: Arthritis, Juvenile Rheumatoid; Medication Adherence; Quality of Life

Summary: the goal of this observational study is to learn about the drug compliance of patients with juvenile idiopathic arthritis and, to figure our factors that affect the compliance. the main questions it aims to answer are: * medication use and compliance in children with chronic diseases is an important problem, but do patients with jia really use their medications in harmony? * does the level of adherence to medications affect the quality of life of patients with jia? participants will be asked to fill the demographic form which includes personal information and nutritional habbits, morisky drug compliance scale - 8 and the pediatric quality of life inventory forms, with attending researcher yesfa sebnem ozbay, m.d. this study is not an interventional study.


Eligibility criteria:
inclusion criteria: * being followed up with the diagnosis of juvenile idiopathic artritis (jia) from the pediatric rheumatology outpatient clinic of istanbul university, istanbul faculty of medicine exclusion criteria: * refusal of patients or their parents to participate in the study * although the patient is followed up with the diagnosis of jia, not using medication
a medical research study to evaluate the effects of act-246475 in adults with coronary artery disease

Conditions: Stable Coronary Artery Disease

Summary: the goal of this study is to find out if a drug called selatogrel (act-246475) can prevent platelets from binding together when administered by an injection under the skin in the thigh or in the belly. another goal is to know how fast and for how long selatogrel (act-246475) works and if there is a difference if the drug is injected in the thigh or in the belly. this study will also help to find out more about the safety of this new drug.

to investigate the pharmacodynamic (pd) and pharmacokinetic (pk) properties of selatogrel in patients with atherosclerotic disease, the present study will be conducted in patients with chronic coronary syndromes (ccs). assessment in a population of patients with ccs allows better control and stability of concomitant treatments, and therefore more accurate characterization of the pharmacodynamic and pharmacokinetic profiles of selatogrel in the presence of background antiplatelet therapies. the study will have 3 periods: a screening period of up to 21 days prior to randomization, a treatment period of 2 days from randomization (day 1) to 24 hours post dose (day 2), and a follow-up period from day 3 to the safety follow-up telephone call 28 to 35 days after single administration of study drug (end-of-study).

Eligibility criteria:
main inclusion criteria: 1. signed informed consent prior to any study-mandated procedure. 2. male and female subjects aged from 18-85 years, inclusive. 3. for women of childbearing potential: negative urine pregnancy test at visit 1 and at visit 2 before randomization. 4. stable coronary artery disease (cad) defined by the presence of any of the following conditions: 1. history of cad with coronary artery stenosis on coronary angiogram ≥50%. 2. previously documented myocardial infarction occurring more than 3 months prior to randomization. 5. antiplatelet background therapy stable for at least 1 month prior to randomization. 6. body weight ≥ 40.0 kg (88.2 lbs). main exclusion criteria: 1. acute coronary syndrome, percutaneous coronary intervention or any intervention for peripheral artery disease within 3 months prior to randomization. 2. acute ischemic stroke or transient ischemic attack (tia) within 3 months prior to randomization. 3. active internal bleeding, or medical history of recent (\< 1 month) bleeding disorders or conditions associated with high risk of bleeding (e.g., clotting disturbances, gastrointestinal bleed, hemoptysis). 4. hemoglobin ≤ 10 g/dl at screening. 5. loss of at least 250 ml of blood within 3 months of screening. 6. use of anticoagulants (oral, parenteral) or fibrinolytic therapy within 24 h prior to screening (visit 1). 7. known platelet disorders (e.g., thrombasthenia, thrombocytopenia, von willebrand disease). 8. pregnant or breastfeeding women.

Keywords: chronic coronary syndrome
horizontal augmentation with deproteinized bovine bone mineral alone or in combination with particulate autogenous bone

Conditions: Edentulous Jaw

Summary: background: placement of oral implants is frequently compromised due to atrophy of the alveolar process. lateral ridge augmentation with an autogenous bone block is frequently necessary to increase the width of the alveolar process before implant installation. however, harvesting of an autogenous bone block is associated with donor site morbidity. consequently, bone substitutes alone or in combination with particulate autogenous bone graft are used increasingly to simplify the surgical procedure. animal and human studies evaluating lateral ridge augmentation with bio-oss alone or in combination with particulate autogenous bone graft have demonstrated new bone formation and high implant survival. however, the optimal ratio of bio-oss and particulate autogenous bone graft for lateral ridge augmentation and long-term implant survival is unknown. purpose: test the h0-hypothesis of no difference in long-term implant survival, newly formed bone, volumetric stability of the graft, gained width of the alveolar process and patient satisfaction after lateral ridge augmentation with bio-oss alone or in combination with a diminutive amount of autogenous bone graft. material and methods: lateral ridge augmentation will be performed in 20 adults with two different ratios of bio-oss and autogenous bone graft after a split mouth design. clinical and radiological measurements will evaluate the long-term implant survival. cone beam computer tomography (cbct) will be obtained preoperatively, immediately postoperatively, prior to implant placement, 2 years after implant installation and 5 years after implant installation to estimate the volumetric changes of the augmented area. moreover, the amount of newly formed bone will be estimated by histologic evaluation after implant placement. conclusion: long-term implant survival has never been evaluated after lateral ridge augmentation with bio-oss alone or in combination with a diminutive amount of autogenous bone graft.


Eligibility criteria:
inclusion criteria: * total or partial bilateral edentulism * horizontal bone width less than 4 mm at planned sites of implant installation or need of augmentation of aesthetic reasons for optimal implant placement exclusion criteria: * uncontrolled systematic disease * history of radiation in the area * smoking habits (free of smoking habits more than 1 month prior to treatment) * treatment with bisphosphonates * patients who cannot complete the 5-year observation period

Keywords: bone substitutes imaging-three-dimensional alveolar ridge augmentation dental implants bio-oss guided bone regeneration
the effect of bedside ultrasound assistance on the proportion of successful infant spinal taps

Conditions: Traumatic Lumbar Puncture

Summary: the reported rate of unsuccessful spinal taps in children, especially young infants, is high. our hypothesis is that ultrasound assistance can improve the success rate of spinal taps.

the reported rate of unsuccessful spinal taps in children is high. at the children's hospital of philadelphia (chop), quality improvement data demonstrates a failure rate of \~40-50%. research has shown that bedside ultrasound can improve visualization and improve the success rate of spinal taps. increasing the proportion of successful spinal taps in the emergency department could significantly reduce the rate of unnecessary hospitalizations, additional interventional procedures and antibiotic use. our objective is to determine if bedside ultrasound-assisted site marking will increase the proportion of first attempt successful spinal taps. this will be a prospective, randomized controlled study that will take place over the course of 18 months with the goal to recruit a sample of approximately 128 patients. we will recruit subjects from the chop emergency department. the patients will be randomized into an ultrasound-assisted group versus a non-ultrasound-assisted group. our hypothesis is that bedside ultrasound-assisted site marking will increase the number of successful spinal taps.

Eligibility criteria:
inclusion criteria: * less than or equal to six months of age * plan for diagnostic or therapeutic lumbar puncture as per front line clinician * availability of a study sonographer to perform bedside ultrasound exclusion criteria: * known spinal cord abnormality (e.g., tethered cord, spina bifida)

Keywords: ultrasound lumbar puncture spinal tap pediatric infant bedside ultrasonography
double-layer artificial dermal repair material combined with growth factors is used for exposed tendon wounds

Conditions: Open Wound of Hip With Tendon Involvement

Summary: compared with the combination of double-layer artificial dermal repair materials combined with growth factors, and the treatment methods using double-layer artificial dermal repair materials, the time and effect of the two treatment regimens on the function and appearance of wound repair with exposed tendon were different, as well as the medical costs.

this study used a prospective cohort study to select all patients who met the inclusion criteria in six hospitals within six months after the start of the trial, including no less than 55 patients receiving artificial dermis combined with growth factor and no less than 110 patients receiving simple artificial dermal treatment, and the cumulative number of patients was not less than 110 patients, to compare the time and effect of the two treatment options on the functional and cosmetic restoration of upper limb wound repair with exposed tendons.

Eligibility criteria:
inclusion criteria: 1. elbow joint to fingertip area, soft tissue defect accompanied by tendon exposed fresh wound, tendon exposed wound area of 2\~20cm2, wound area 5-600cm2, need to transplant autologous skin; 2. incomplete aponeurosis; 3. voluntarily sign the informed consent form. for persons with no or limited capacity for civil conduct, obtain the consent of their guardians and sign an informed consent form. exclusion criteria: 1. wound infection or suspected osteomyelitis; 2. chronic wounds; 3. more than 2/3 of the exposed tendons are suspended on the wound surface; 4. those with serious primary diseases such as cardiovascular and cerebrovascular, liver and kidney and hematopoietic system, which cannot be treated by surgery; 5. those who are allergic to collagen and chondroitin sulfate; 6. other persons that the investigator deems unsuitable.
safety and pharmacokinetics of abicipar pegol intravitreal injections in patients with neovascular amd

Conditions: Macular Degeneration

Summary: this study will evaluate the safety and characterize the systemic pharmacokinetics (pk) of free and vascular endothelial growth factor (vegf)-bound abicipar following single and multiple intravitreal injections of abicipar pegol in treatment-naïve patients with neovascular age-related macular degeneration (amd).


Eligibility criteria:
inclusion criteria: -presence of active subfoveal and/or juxtafoveal choroidal neovascularization (cnv) secondary to age-related macular degeneration (amd). exclusion criteria: * history of or active periocular, ocular, or intraocular infection. * previous use of verteporfin photodynamic therapy (pdt) or any ocular anti-angiogenic therapy (eg, aflibercept, bevacizumab, ranibizumab, pegaptanib), approved or investigational, for the treatment of neovascular amd or previous therapeutic radiation in the region. * prior use of ocular anti-vegf agents for neovascular eye diseases other than amd. * macular hemorrhage that involves the center of fovea in the study eye. * any prior or current systemic or ocular treatment (including surgery) for neovascular amd in the study eye. * treatment with ocular corticosteroid injections or implants within 6 months in the study eye. * history or evidence of eye surgery: pars plana vitrectomy, submacular surgery or other surgical interventions for amd, incisional glaucoma surgery or cataract or refractive surgery within the last 3 months. * amd in the non-study eye that requires anti-vegf treatment.